Daiichi Sankyo subsidiary acquires PharmaForce

Daiichi Sankyo has revealed that one of its subsidiaries – Luitpold Pharmaceuticals – has acquired PharmaForce.

As of December 29th 2009, 100 per cent of the stock of PharmaForce – a privately-held, fully integrated specialty injectable pharmaceutical organisation – was purchased by Luitpold.

The company was founded in 1999 and develops and markets a number of difficult-to-manufacture sterile products and first-to-market
generic injectable products.

Mary Jane Helenek, president and chief executive officer of Luitpold, said: “The acquisition of PharmaForce is another important step in the implementation of Luitpold’s strategic plan to further diversify our product portfolio and generate additional growth.”

Meanwhile, Daiichi Sankyo revealed in November that objections raised over its right to market levofloxacin in the UK were dismissed in court.

Generics UK’s opposition to the move was quashed as Daiichi Sankyo’s supplementary protection certificate was decalred legally valid.